About Axial Spondyloarthritis Treatment
Axial spondyloarthritis treatment market covers the drugs used for the treatment of inflammatory rheumatic disease, which predominantly affects the spine and sacroiliac joints.
Technavio’s analysts forecast the Global Axial Spondyloarthritis Treatment Market to grow at a CAGR of 7.37% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the axial spondyloarthritis treatment market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of axial spondyloarthritis across the globe.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, axial spondyloarthritis treatment market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AbbVie
• Amgen
• Johnson & Johnson
• Pfizer
• UCB
Market driver
• Increase in the number of approved biosimilars
• For a full, detailed list, view our report
Market challenge
• High cost of biologics
• For a full, detailed list, view our report
Market trend
• Increase in the number of small molecules in the drug development pipeline
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY CATEGORY
• Segmentation by category
• Comparison by category
• Global ankylosing spondylitis treatment market – Market size and forecast 2017-2022
• Global non-radiographic axial spondyloarthritis treatment market – Market size and forecast 2017-2022
• Market opportunity by category
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie
• Amgen
• Johnson & Johnson
• Pfizer
• UCB
PART 16: APPENDIX
• List of abbreviations
?
?
Exhibit 01: Parent market
Exhibit 02: Global axial spondyloarthritis treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global axial spondyloarthritis treatment market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global axial spondyloarthritis treatment market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape by development phase 2018
Exhibit 19: Key clinical trial candidates of axial spondyloarthritis 2017-2018
Exhibit 20: Global axial spondyloarthritis treatment market by category– Market share 2017-2022 (%)
Exhibit 21: Comparison by category
Exhibit 22: Global ankylosing spondylitis treatment market – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global ankylosing spondylitis treatment market – Year-over-year growth 2018-2022 (%)
Exhibit 24: Global non-radiographic axial spondyloarthritis treatment market – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Global non-radiographic axial spondyloarthritis treatment market – Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by category
Exhibit 27: Customer landscape
Exhibit 28: Global axial spondyloarthritis treatment market by geography – Market share 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in the Americas
Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: AbbVie: Overview
Exhibit 46: AbbVie – Business segments
Exhibit 47: AbbVie – Organizational developments
Exhibit 48: AbbVie – Geographic focus
Exhibit 49: AbbVie – Key offerings
Exhibit 50: AbbVie – Key customers
Exhibit 51: Amgen: Overview
Exhibit 52: Amgen – Business segments
Exhibit 53: Amgen – Organizational developments
Exhibit 54: Amgen – Geographic focus
Exhibit 55: Amgen – Key offerings
Exhibit 56: Amgen – Key customers
Exhibit 57: Johnson & Johnson: Overview
Exhibit 58: Johnson & Johnson– Business segments
Exhibit 59: Johnson & Johnson– Organizational developments
Exhibit 60: Johnson & Johnson– Geographic focus
Exhibit 61: Johnson & Johnson– Segment focus
Exhibit 62: Johnson & Johnson– Key offerings
Exhibit 63: Johnson & Johnson– Key customers
Exhibit 64: Pfizer: Overview
Exhibit 65: Pfizer – Business segments
Exhibit 66: Pfizer – Organizational developments
Exhibit 67: Pfizer – Geographic focus
Exhibit 68: Pfizer– Segment focus
Exhibit 69: Pfizer – Key offerings
Exhibit 70: Pfizer – Key customers
Exhibit 71: UCB: Overview
Exhibit 72: UCB – Business segments
Exhibit 73: UCB – Organizational developments
Exhibit 74: UCB – Geographic focus
Exhibit 75: UCB – Key offerings
Exhibit 76: UCB – Key customers
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY CATEGORY
• Segmentation by category
• Comparison by category
• Global ankylosing spondylitis treatment market – Market size and forecast 2017-2022
• Global non-radiographic axial spondyloarthritis treatment market – Market size and forecast 2017-2022
• Market opportunity by category
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie
• Amgen
• Johnson & Johnson
• Pfizer
• UCB
PART 16: APPENDIX
• List of abbreviations
?
?
Exhibit 01: Parent market
Exhibit 02: Global axial spondyloarthritis treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global axial spondyloarthritis treatment market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global axial spondyloarthritis treatment market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape by development phase 2018
Exhibit 19: Key clinical trial candidates of axial spondyloarthritis 2017-2018
Exhibit 20: Global axial spondyloarthritis treatment market by category– Market share 2017-2022 (%)
Exhibit 21: Comparison by category
Exhibit 22: Global ankylosing spondylitis treatment market – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global ankylosing spondylitis treatment market – Year-over-year growth 2018-2022 (%)
Exhibit 24: Global non-radiographic axial spondyloarthritis treatment market – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Global non-radiographic axial spondyloarthritis treatment market – Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by category
Exhibit 27: Customer landscape
Exhibit 28: Global axial spondyloarthritis treatment market by geography – Market share 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in the Americas
Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: AbbVie: Overview
Exhibit 46: AbbVie – Business segments
Exhibit 47: AbbVie – Organizational developments
Exhibit 48: AbbVie – Geographic focus
Exhibit 49: AbbVie – Key offerings
Exhibit 50: AbbVie – Key customers
Exhibit 51: Amgen: Overview
Exhibit 52: Amgen – Business segments
Exhibit 53: Amgen – Organizational developments
Exhibit 54: Amgen – Geographic focus
Exhibit 55: Amgen – Key offerings
Exhibit 56: Amgen – Key customers
Exhibit 57: Johnson & Johnson: Overview
Exhibit 58: Johnson & Johnson– Business segments
Exhibit 59: Johnson & Johnson– Organizational developments
Exhibit 60: Johnson & Johnson– Geographic focus
Exhibit 61: Johnson & Johnson– Segment focus
Exhibit 62: Johnson & Johnson– Key offerings
Exhibit 63: Johnson & Johnson– Key customers
Exhibit 64: Pfizer: Overview
Exhibit 65: Pfizer – Business segments
Exhibit 66: Pfizer – Organizational developments
Exhibit 67: Pfizer – Geographic focus
Exhibit 68: Pfizer– Segment focus
Exhibit 69: Pfizer – Key offerings
Exhibit 70: Pfizer – Key customers
Exhibit 71: UCB: Overview
Exhibit 72: UCB – Business segments
Exhibit 73: UCB – Organizational developments
Exhibit 74: UCB – Geographic focus
Exhibit 75: UCB – Key offerings
Exhibit 76: UCB – Key customers
